We evaluated the clinical performances of the immunoenzymometric assays for type I collagen Nterminal and C-terminal telopeptides and the HPLC assay for total deoxypyridinoline, in distinguishing between subjects with a moderately increased bone resorption rate (women in postmenopause) and subjects with normal bone resorption rate (women in premenopause). The postmenopausal group consisted of 61 women who had been in menopause for no more than 10 years, while the premenopausal group consisted of 52 healthy women with normal menstrual cycles. The biochemical markers were measured in a 24 hour urine sample and the results expressed as the molar ratio with urinary creatinine. The clinical performances were estimated by calculating the accuracy (as the area under a Receiver Operated Characteristic (ROC) curve: mean ± SEM) and the discriminating power (as score) of each assay in distinguishing postmenopausal subjects from premenopausal subjects. Type I collagen C-terminal telopeptide, type I collagen N-terminal telopeptide and total deoxypyridinoline were significantly higher in the postmenopausal than in the premenopausal group (p < 0.001). Accuracies of these three markers ranged from 66.8 ± 5.1% to 76.8 ± 4.3%, while Z scores ranged from 3.54 to 5.67. Type I collagen C-terminal telopeptide, type I collagen N-terminal telopeptide and total deoxypyridinoline were not significantly different in their accuracy or discriminating power. All markers were highly correlated with coefficients of correlation ranging from 0.61 to 0.77.
Introduction
dinium cross-links were shown to be relatively efficient
The use of biochemical markers of bone resorption in estimatin g both s ™ n and bi S differences in bone reseems increasingly important in the diagnosis and folsor P lon ra e ^ ' '' low-up of metabolic bone diseases, particularly osteo-Unfortunately these assays, particularly the pyridinium porosis. In a previous paper Bettica and colleagues (1) cross-links, are time-consuming (3), and an immunomethave shown that hydroxyproline, the time-honoured bio-ric assay is desirable. In recent months, different immuchemical marker of bone resorption, is adequate for dis-noenzymometric assays that measure type I collagen teltinguishing subjects with large increases in bone resorp-opeptides (both C-and N-terminal) have been proposed tion rate (Pagencs and children) from normal subjects, (4, 5) , and preliminary data on these assays in different but has limited use in estimating small differences in metabolic bone diseases have shown promising results bone resorption rate (postmenopausal osteoporosis). On (4, 5) . However, to the best of our knowledge, the clinthe other hand, galactosyl hydroxylysine and the pyri-ical performances of these new assays have not yet been compared in the same subjects, in order to establish their respective accuracies in discriminating different rates of bone resorption.
This study sought to evaluate the clinical performances of these new immunoenzymometric assays in comparison with those of the HPLC assay for total deoxypyridinoline, and to estimate the relationships among these markers.
Patients and Methods
Two groups of subjects were selected for the study. The control group (premenopausal) consisted of 52 women with regular menstrual cycle and regular ovulation (as demonstrated by a serum progesterone level > 5 g/l around the 20th day of cycle) with an age of 34.2 ±5.8 years (mean ± SD), recruited among the hospital personnel; none of them had any disease or was taking any medication known to affect bone turnover. Their weight was 62.2 ±8.1 kg and their height 160.3 ± 11 cm. The second group (postmenopausal) consisted of 61 women in postmenopause (< 10 years; mean 7.1 ± 3.7 years) with an age of 57.3 ± 3.5 years, who attended our Endocrinology Outpatient Clinic. Their weight was 61.4 ± 8.3 kg and their height 159.4 ± 5.5 cm. The bone mineral density of the spine of the postmenopausal group (measured by dual X-ray absorptiometry in the anteroposterior projection with a QDR2000 bone densitometer, Hologic) was 0.821 ± 0.071 g/cm 2 , corresponding to a t score of -2.31 ± 0.66 (calculated using the normal young female Caucasian database provided by Hologic). None of the subjects in the postmenopausal group was taking any medication known to affect bone turnover.
All subjects collected a 24 hour urine sample and aliquots were stored at -20 °C until use. Total deoxypyridinoline, type I collagen N-terminal telopeptide, type I collagen C-terminal telopeptide and creatinine were measured. All samples were measured in the same run to avoid inter-assay variation.
Total deoxypyridinoline was measured by HPLC with a commercial kit (Chrom-Links in HPLC, BIORAD). Type I collagen Nterminal telopeptide was measured with a commercial kit with a monoclonal antibody specific for the cross-linked type I collagen N-terminal telopeptide (Osteomark, Ostex, USA). Type I collagen C-terminal telopeptide was measured with a commercial kit (Crosslaps ELISA, Osteometer, Denmark) with a polyclonal antibody raised against a synthetic sequence of type I collagen C-terminal telopeptide. Creatinine was measured by an automatic assay based on the Jaffe method.
Statistics
The clinical performances of the different markers were estimated by calculating the accuracy and the discriminating power a distinguishing postmenopausal from premenopausal women (1). The accuracy was calculated as the mean ± SEM area under a receiver operated characteristic (ROC) curve that was drawn by calculating the sensitivity and the false positive ratio at nine different threshold values (6) . The method used to select the threshold values was the same for each assay. The values selected ranged from mean -2 SD to mean + 2 SD of the control subjects. The discriminating power was calculated as the Z score with the aid of the following formula Finally, to test the agreement among total deoxypyridinoline, type I collagen N-terminal telopeptide and type I collagen Cterminal telopeptide, we calculated for each postmenopausal woman and for each marker a t score (t score = (postmenopausal subject value -premenopausal mean value)/premenopausal standard deviation) and for each pair of markers we estimated the correlation between the mean t score (independent variable) and the difference between the t scores (dependent variable) by the method of Bland & Altman (8) .
Results
As shown in figure 1 the urinary excretion of total deoxypyridinoline/creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creatinine was significantly higher in postmenopausal women. The mean increase was 32% for total deoxypyridinoline/creatinine, 31% for type I collagen N-terminal telopeptide/creatinine and 65% for type I collagen C-terminal telopeptide/creatinine. Table 1 shows the clinical performances of the three markers. The accuracies of total deoxypyridinoline/ creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creatinine were comparable and ranged from 66.8 ±5.1% (type I collagen N-terminal telopeptide/creatinine) to 76.8 ± 5.3% (type I collagen C-terminal telopeptide/ creatinine). The discriminate powers ranged from 3.54 (type I collagen N-terminal telopeptide/creatinine) to 5.67 (type I collagen C-terminal telopeptide/creatinine). The accuracies and discriminating powers were not significantly different for each of the three markers.
As shown in table 2 all the markers were highly correlated with coefficients of correlation ranging from 0.61 (total deoxypyridinoline vs type I collagen Cterminal telopeptide) to 0.77 (total deoxypyridinoline vs type I collagen N-terminal telopeptide) when the absolute values were considered (tab. 2a), and from 0.502 (total deoxypyridinoline/creatinine vs type I collagen C-terminal telopeptide/creatinine) to 0.681 (type I collagen N-terminal telopeptide/creatinine vs type I collagen C-terminal telopeptide/creatinine) when creatinine ratios were used (tab. 2b). As shown in figure 2 there was also a good agreement among the three markers, since none of the slopes of the linear regressions, calculated according to the method of Bland & Altman (8) , was significantly different from zero. Good agreement between the three markers is also indicated by the fact that there was no improvement in accuracy in distinguishing premenopausal and postmenopausal women when total deoxypyridinoline, type I collagen N-terminal telopeptide and type I collagen C-terminal telopeptide were used in series (i.e. a result is positive when both test results are above the threshold value) or in parallel (i. e. a result is positive when at least one test result is above the threshold value) (tab. 3). Results are mean ± SD. For all three markers postmenopausal women showed a significantly larger excretion than premenopausal women (p < 0.001).
Discussion
When measured in urine, a biochemical marker of bone resorption ideally has the four following properties.
1) Bone specificity.
2) Specificity for bone resorption.
3) Absence of metabolism and clearance from the body only by the kidney.
4) Specificity, sensitivity, reproducibility and simplicity of the assay.
A marker with such characteristics would be highly accurate in distinguishing subjects with different bone resorption rates. Hydroxyproline is neither specific for bone (9-12) nor for bone resorption (10), moreover it is mostly metabolised before being excreted in urine (13) . As a consequence hydroxyproline is a poor bone resorption marker (1). In the search of specific markers of bone resorption, different molecules have been proposed in recent years. In particular, great interest has been shown in the study of pyridinium crosslinks and of type I collagen telopeptides. Regarding pyridinium cross-links, pyridinoline is present in many different tissues (14) and deoxypyridinoline has been detected in bone, dentine, aorta and ligaments (15) . Both molecules are formed during collagen maturation, and are therefore released from tissues only following collagen degradation. Nothing is known about the presence or absence of metabolism, or the extent of renal excretion of these molecules. In particular, since urinary pyridinium cross-links are 40% free and 60% peptide-bound (16), we do not know whether they are released from bone in this proportion, or whether they become free due to the action of circulating or renal peptidases. Total pyridinium cross-links are measured by HPLC with an assay that is specific Tab. 1 Accuracies (mean ± SEM) and discriminating powers (Z score) of total deoxypyridinoline/creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creatinine in distinguishing postmenopausal subjects from premenopausal subjects. Tab. 2b Coefficients of correlation (r) among total deoxypyridinoline/creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creatinine. Data are expressed as umol/mol of creatinine (total deoxypyridinoline and type I collagen N-terminal telopeptide) or μg/mol of creatinine (type I collagen C-terminal telopeptide). All coefficients are highly significant (p < 0.0001, n = 113).
Total deoxypyridinoline/ creatinine
Type I collagen C-terminal telopeptide/ creatinine and sensitive, but time-consuming (3). Type I collagen telopeptides are present in all tissues that contain type I collagen (4, 5) , the largest portion being bone. The method used to measure type I collagen N-terminal telopeptide uses the cross-linked telopeptide as the antigen (4); therefore the measured type I collagen Nterminal telopeptides arise from mature collagen degradation. The method used to measure type I collagen C-terminal telopeptide uses, as the antigen, a synthetic peptide corresponding to eight amino acids of the Cterminal telopeptide of the c^ chain of type I collagen, and it does not contain a pyridinium cross-link (5); therefore the possibility of measuring peptides that derive from collagen that was degraded before deposition cannot be excluded a priori. Very little is known about the fate of the telopeptides after their release from tissues. In this regard, a recent study has shown that type I collagen N-terminal telopeptide is released as such from bone resorbed by osteoclasts (17) . Type I collagen N-terminal telopeptide and type I collagen Cterminal telopeptide are measured by immunoenzymometric assays, which are specific, sensitive, fairly reproducible and simple (4, 5) . Altogether these data show that total deoxypyridinoline, type I collagen Nterminal telopeptide and type I collagen C-terminal telopeptide fulfil part of the requirements for an ideal bone resorption marker. In this study we evaluated whether these tests were able to distinguish different rates of bone resorption. For this purpose, we eval- Tab. 3 Accuracies (mean ± SEM), in distinguishing premenopausal and postmenopausal women, of the combined use of total deoxypyridinoline/creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creati-
In series
In parallel 69. 4 ± 4.9 69.7 ± 4.9
Type I collagen N-terminal 49.1 ± 5.5 telopeptide/creatinine + type I collagen C-terminal telopeptide/creatinine Type I collagen N-terminal 48.7 ± 5.5 telopeptide/creatinine + total deoxypyridinoline/creatinine Type I collagen C-terminal 51.2 ± 5.5 telopeptide/creatinine + total deoxypyridinoline/creatinine uated the accuracy and the discriminating power of the tests in distinguishing a group of women in early postmenopause, i. e. a group of subjects with a moderate increase in bone resorption rate, from a group of premenopausal women, i.e. a group of subjects with a normal bone resorption rate.
Accuracy defines how often a test is able to place correctly a subject in the group he or she belongs to for a certain characteristic, in our case the bone resorption rate (18) . The major factors that influence the estimate of the accuracy of a test are the "true disease status" (in our case the moderately increased bone resorption rate in the postmenopausal group) and the decision biases (19) . Regarding the "true disease status", a moderate increase in bone resorption rate has been shown for women after menopause (20) , which in turn determines an increase in the urinary excretion of the markers tested in this study (5, 21 -23) . Regarding the decision biases, the receiver operated characteristic (ROC) curve analysis, that estimates the accuracy of a test using different threshold values, avoids such an interfering factor (19) . Type I collagen C-terminal telopeptide, type I collagen N-terminal telopeptide and total deoxypyridinoline showed a comparatively high accuracy in placing the premenopausal subjects in the group with normal bone resorption rate and the postmenopausal subjects in the group with a moderately increased bone resorption rate. The accuracies ranged from 66.8 ± 5.1% for type I collagen Nterminal telopeptide/creatinine to 76.8 ± 4.3% for type I collagen C-terminal telopeptide/creatinine, and were not significantly different.
The discriminating power, on the other hand, defines how well a test distinguishes two groups of subjects that differ for a certain characteristic, which in our case was again the bone resorption rate. The test with the highest discriminating power will be the test that shows the highest difference between the mean of the two groups with the lowest dispersion. A Z score higher than 3 defines a high discriminating power. The differences between the mean of the premenopausal and postmenopausal groups were not similar for total deoxypyridinoline/creatinine, type I collagen N-terminal telopeptide/creatinine and type I collagen C-terminal telopeptide/creatinine, ranging from 31% for type I collagen N-terminal telopeptide/ creatinine to 65% for type I collagen C-terminal telopeptide/creatinine. However, the estimated discriminating powers were not significantly different, suggesting that the tests that show the biggest difference between the mean of the two groups have also a bigger dispersion around the mean. Since all the assays employed in this study have similar coefficients of variation (CV < 10%), these differences in variability might rather be due to the biological variance of the markers.
The secondary aim of this study was to evaluate the relationships among the markers tested. To do so, we used both the urinary concentrations of the markers and the creatinine ratio, to ensure that the relationships among the markers were not influenced by their relationship with creatinine excretion and by sample dilution. All markers were highly correlated both when absolute values and creatinine ratios were used, confirming previous publications (4, 5, 21, 24, 25) .
Finally, we evaluated the extent of agreement among the results obtained with the three different tests. For this purpose, we used the method of Bland & Altman (8) which evaluates the agreement of two tests by calculating the linear regression between the mean of the two tests (independent variable) and the difference of the two tests (dependent variable). A non-significant regression shows that the two tests analysed are in good agreement. To normalize the results obtained with total deoxypyridinoline, type I collagen N-terminal telopeptide and type I collagen C-terminal telopeptide, we calculated for each assay and each postmenopausal woman a t score, and we used the mean and the difference of the t scores in the linear regression. The calculated linear regression (8) showed a non-significant slope for all markers, demonstrating that the results obtained with type I collagen N-terminal telopeptide, type I collagen C-terminal telopeptide and total deoxypyridinoline are in good agreement.
In conclusion we showed that the new immunoenzymometric assays that measure N-terminal and C-terminal telopeptides of type I collagen have the same accuracy and discriminating power of the HPLC assay for total deoxypyridinoline in distinguishing subjects with moderately increased bone resorption rate from normal subjects. Our data on the relationship among these three markers show that these markers are correlated and in good agreement, thus supporting the use of all these assays for estimting bone resorption in the diagnosis and follow-up of osteoporosis.
